- Home
- KLRS vs GROV Comparison
KLRS vs GROV Comparison
Compare KLRS & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- GROV
- Stock Information
- Founded
- KLRS 2019
- GROV 2016
- Country
- KLRS United States
- GROV United States
- Employees
- KLRS N/A
- GROV N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- GROV Package Goods/Cosmetics
- Sector
- KLRS Health Care
- GROV Consumer Discretionary
- Exchange
- KLRS Nasdaq
- GROV Nasdaq
- Market Cap
- KLRS 46.0M
- GROV 53.5M
- IPO Year
- KLRS N/A
- GROV N/A
- Fundamental
- Price
- KLRS $3.71
- GROV $1.54
- Analyst Decision
- KLRS Strong Buy
- GROV Buy
- Analyst Count
- KLRS 2
- GROV 2
- Target Price
- KLRS $23.00
- GROV $1.35
- AVG Volume (30 Days)
- KLRS 689.3K
- GROV 51.9K
- Earning Date
- KLRS 11-15-2025
- GROV 11-11-2025
- Dividend Yield
- KLRS N/A
- GROV N/A
- EPS Growth
- KLRS N/A
- GROV N/A
- EPS
- KLRS N/A
- GROV N/A
- Revenue
- KLRS N/A
- GROV $185,354,000.00
- Revenue This Year
- KLRS N/A
- GROV N/A
- Revenue Next Year
- KLRS N/A
- GROV $11.10
- P/E Ratio
- KLRS N/A
- GROV N/A
- Revenue Growth
- KLRS N/A
- GROV N/A
- 52 Week Low
- KLRS $2.14
- GROV $1.02
- 52 Week High
- KLRS $24.15
- GROV $1.95
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- GROV 57.35
- Support Level
- KLRS $2.37
- GROV $1.49
- Resistance Level
- KLRS $4.90
- GROV $1.59
- Average True Range (ATR)
- KLRS 0.70
- GROV 0.04
- MACD
- KLRS -0.02
- GROV -0.00
- Stochastic Oscillator
- KLRS 24.95
- GROV 50.00
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.